Výsledky vyhledávání - "Franklin J. Zieve"

Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial

Autor: Paul D. Thompson, Christopher P. Cannon, Eric Bruckert, Franklin J. Zieve, Marie T. Baccara-Dinet, Jian Zhao, Jean Bergeron, Garen Manvelian, Shazia Ali, Terry A. Jacobson, John R. Guyton, Patrick M. Moriarty, Stephen Donahue, Robert Pordy

Publikováno v: Journal of clinical lipidology. 14(1)

Background The 24-week randomized, double-blind ODYSSEY ALTERNATIVE trial (NCT01709513) demonstrated significant low-density lipoprotein cholesterol (LDL-C) reductions with the PCSK9 inhibitor alirocumab vs ezetimibe in statin-intolerant patients, wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef024f55093bf342d11950da6b5f8bb2
https://pubmed.ncbi.nlm.nih.gov/32192644

Zobrazit plný text záznamu

Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapy

Autor: JoAnne M. Foody, W. Virgil Brown, Franklin J. Zieve, Andrew M. Tershakovec, Arvind Shah, Joanne E. Tomassini

Publikováno v: Journal of Clinical Lipidology. 10:116-123

Background Little is known regarding relationships between high-sensitivity C-reactive protein (hsCRP) and lipoproteins other than low-density lipoprotein cholesterol (LDL-C). High-density lipoprotein (HDL), with both anti-inflammatory and cholestero

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f63ed2296fda645c0f35013599ec4b3
https://doi.org/10.1016/j.jacl.2015.10.002

Zobrazit plný text záznamu

The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial

Autor: William C, Duckworth, Carlos, Abraira, Thomas E, Moritz, Stephen N, Davis, Nicholas, Emanuele, Steven, Goldman, Rodney, Hayward, Grant D, Huang, Jennifer B, Marks, Peter D, Reaven, Domenic J, Reda, Stuart R, Warren, Franklin J, Zieve, Virginia, Easton

Publikováno v: Journal of Diabetes and its Complications. 25:355-361

The goal of the VA Diabetes Trial (VADT) was to determine the effect of intensive glucose control on macrovascular events in subjects with difficult-to-control diabetes. No significant benefit was found. This report examines predictors of the effect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39d28058e426808a056ee8650f51e8d2
https://doi.org/10.1016/j.jdiacomp.2011.10.003

Zobrazit plný text záznamu

The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years

Autor: Franklin J. Zieve, Christian Constance, Nanette K. Wenger, Charlotte Jones-Burton, Mary E. Hanson, Andrew M. Tershakovec, Arvind Shah, Ori Ben-Yehuda, Jianxin Lin

Publikováno v: Journal of Geriatric Cardiology. 8:1-11

Background Coronary heart disease (CHD) risk increases with age; yet lipid-lowering therapies are significantly under-utilized in patients > 65 years. The objective was to evaluate the safety and efficacy of lipid-lowering therapies in older patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c77f924aef25cd7e6a54ff17039e3bd9
https://doi.org/10.3724/sp.j.1263.2011.00001

Zobrazit plný text záznamu

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

Autor: William, Duckworth, Carlos, Abraira, Thomas, Moritz, Domenic, Reda, Nicholas, Emanuele, Peter D, Reaven, Franklin J, Zieve, Jennifer, Marks, Stephen N, Davis, Rodney, Hayward, Stuart R, Warren, Steven, Goldman, Madeline, McCarren, Mary Ellen, Vitek, William G, Henderson, Grant D, Huang, V, Easton

Publikováno v: New England Journal of Medicine. 360:129-139

The effects of intensive glucose control on cardiovascular events in patients with long-standing type 2 diabetes mellitus remain uncertain.We randomly assigned 1791 military veterans (mean age, 60.4 years) who had a suboptimal response to therapy for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a58cae8f5b02f7f1056da73a4f4fd2cf
https://doi.org/10.1056/nejmoa0808431

Zobrazit plný text záznamu

Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes

Autor: Michael R. Jones, Sherwyn Schwartz, William L. Bailey, Franklin J. Zieve, Marcia F. Kalin

Publikováno v: Clinical Therapeutics. 29:74-83

Objective: This study evaluated the glycosylated hemoglobin (HbA 1c -lowering effect of colesevelam hydrochloride, a bile acid sequestrant, in subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy. Metho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c365c1436ca265de48f278f5b1c87827
https://doi.org/10.1016/j.clinthera.2007.01.003

Zobrazit plný text záznamu

Comparison of Efficacy and Safety of Rosuvastatin Versus Atorvastatin in African-American Patients in a Six-Week Trial

Autor: Joseph Ycas, Keith C. Ferdinand, B. Waine Kong, Luther T. Clark, Clinton D. Brown, Franklin J. Zieve, William R. Cox, Philip T. Sager, Jonathan L. Isaacsohn, Boisey O. Barnes, Ryan C. Neal, Karol E. Watson, Alex Gold

Publikováno v: The American Journal of Cardiology. 97:229-235

The lipid-modifying effects of statin therapy in hypercholesterolemic African-Americans have not been well characterized. This study compared the efficacy and safety of rosuvastatin and atorvastatin treatment for 6 weeks in hypercholesterolemic Afric

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f7299d1652cfa9e3c1fa79c3c2c887a
https://doi.org/10.1016/j.amjcard.2005.08.026

Zobrazit plný text záznamu

Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks

Autor: William Insull, Stephanie Kafonek, David Goldner, Franklin J. Zieve

Publikováno v: The American Journal of Cardiology. 87:554-559

The 6-week efficacy and safety of atorvastatin versus simvastatin was determined during a 54-week, open-label, multicenter, parallel-arm, treat-to-target study. In all, 1,424 patients with mixed dyslipidemia (triglyceride 200 to 600 mg/dl [2.26 to 6.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::47f30009bffcaf41d0f0e4d153da1041
https://doi.org/10.1016/s0002-9149(00)01430-2

Zobrazit plný text záznamu

Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care

Autor: Laura A. Petersen, Supicha S. Chitwood, Franklin J. Zieve, Cassie R. Landrum, Degang Wang, Salim S. Virani, Christie M. Ballantyne, LeChauncy D. Woodard

Publikováno v: Journal of clinical lipidology. 6(6)

The Adult Treatment Panel III guidelines established non-high-density lipoprotein cholesterol (non-HDL-C) as a secondary treatment target. However, non-HDL-C levels are not reported on standard lipid panels by many hospital-based and/or commercial bi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80d0b644f6b2353c7af256b9832754f3
https://pubmed.ncbi.nlm.nih.gov/23312050

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání